Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA H1047L |
Therapy | Palbociclib + PF-04691502 |
Indication/Tumor Type | oral squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047L | oral squamous cell carcinoma | sensitive | Palbociclib + PF-04691502 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, oral squamous cell carcinoma cells harboring PIK3CA H1047L demonstrated increased sensitivity to Ibrance (palbociclib) when combined with PF-04691502, and the combination treatment inhibited proliferation in cell culture, and reduced tumor growth in a cell line xenograft model (PMID: 31516747). | 31516747 |
PubMed Id | Reference Title | Details |
---|---|---|
(31516747) | Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. | Full reference... |